Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several safety-monitoring concepts are broadly consistent with label excerpts (e.g., transaminase monitoring prior to and at 12 weeks), but multiple hepatotoxicity/alcohol-specific claims are unsupported or not present in the provided label excerpts, and some statements overreach beyond what the label text supports.
Category Scores
Accurate Statements
LIPITOR can cause liver damage in some individuals.
Supported in part by label Section 5.2 (Liver Dysfunction) describing persistent transaminase elevations and liver function testing; label also reflects serious hepatic adverse outcomes in Section 6.2 (e.g., hepatic failure).
Monitoring liver function while taking LIPITOR can help minimize the risk of liver damage.
Label Section 5.2 states 'Liver function tests be performed prior to and at 12 weeks…' supporting the practice of monitoring.
Regular blood tests can detect abnormalities in liver function while taking Lipitor.
Label Section 5.2 explicitly recommends liver function tests prior to and at 12 weeks.
Unsupported Statements
Alcohol is a liver toxin that can cause liver damage and disease with excessive consumption.
No alcohol-specific statement is present in the provided LIPITOR FDA label excerpts.
When combined with Lipitor, excessive alcohol consumption may increase the risk of liver damage.
No alcohol/LIPITOR interaction or alcohol risk statement is present in the provided label excerpts.
Both Lipitor and alcohol can cause liver inflammation and damage.
The provided label excerpts do not link alcohol with LIPITOR-induced liver inflammation/damage.
A study in the Journal of Clinical Pharmacology found patients taking Lipitor who consumed alcohol were at a higher risk of liver damage than those who did not consume alcohol.
The provided label excerpts do not mention this study.
In that study, consuming more than two drinks per day was associated with a significantly higher risk of liver damage than consuming fewer than two drinks per day.
The provided label excerpts do not include this alcohol threshold or study result.
The risk of liver damage from Lipitor is small but not zero.
While the label provides an incidence for persistent transaminase elevations (0.7%), it does not provide a statement phrased as 'risk of liver damage is small but not zero,' nor a direct alcohol-modified risk estimate in the provided excerpts.
When combined with excessive alcohol consumption, the risk of liver damage may increase.
Alcohol-specific risk modification is not supported by the provided label excerpts.
The FDA has issued a warning about the risks of liver damage associated with statins, including Lipitor.
The provided label excerpts do not reference a specific FDA-issued warning.
Patients taking statins should report symptoms of liver damage to their doctor immediately.
The provided label excerpts do not include patient counseling phrased as 'report symptoms of liver damage immediately.'
Symptoms of liver damage while taking Lipitor can include fatigue, nausea, and abdominal pain.
The provided label excerpts do not list these symptoms as indicators of liver damage.
If symptoms of liver damage occur while taking Lipitor, a doctor may recommend stopping the medication or reducing the dosage.
The provided label excerpts do not provide this symptom-triggered management guidance.
Moderate alcohol consumption (up to two drinks per day) while taking Lipitor is generally considered safe.
The provided label excerpts do not support an alcohol 'two drinks/day' safety statement.
Contradictions
Important Omissions
Label-supported liver monitoring details: 'Liver function tests be performed prior to and at 12 weeks' (and the label’s framing of transaminase elevation persistence and the specific threshold '>3 times the upper limit of normal [ULN]').
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Alcohol-related claims (including a specific 'up to two drinks/day' safety statement and alcohol/LIPITOR risk increase) are unsupported by the provided LIPITOR label excerpts. Unsupported guidance about safety/behavior could mislead patients. Some label-consistent monitoring statements were included.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple alcohol-specific and symptom/management statements are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or replace alcohol-interaction and alcohol dose-threshold safety claims with statements directly supported by the label (e.g., contraindications for active liver disease, and liver function testing prior to and at 12 weeks). Avoid listing specific liver-damage symptom examples or symptom-triggered dosing changes unless present in the provided label.